Next 10 |
home / stock / tbgnf / tbgnf news
Publication Annual Report – Annual Shareholders' Meeting Leuven, BELGIUM – April 15, 2024 – 05:00 PM CET Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, has today published its annual report for the financial year 2023. The...
Oxurion Receives EUR 450,000 in the framework of the Atlas Funding Program Eleventh tranche fully issued and paid-up Leuven, BELGIUM, 10 April 2024 – 07.00 PM CET – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company based in Leuven, today communicates ...
Postponement Annual Shareholders Meeting - Amendment financial calendar Leuven, BELGIUM – April 5, 2024 – 02:00 PM CET Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, today made the following announcement regarding its financial c...
Information on the Total Number of Voting Rights (Denominator) following Conversion Notices from Atlas - Amended version Atlas Special Opportunities, LLC has converted 6 convertible bonds in Oxurion resulting in a EUR 150,000 capital increase. This is part of Atlas Special Opportunities...
OXURION announces its presence at the Paris SmallCap event on March 28, 2024. Leuven, BELGIUM - March 25, 2024 - 7:00 p.m, Oxurion NV (Euronext Brussels : OXUR), a Leuven-based biopharmaceutical company, is pleased to announce its participation in the SmallCap event, scheduled for Mar...
Oxurion Receives EUR 300,000 in the framework of the Atlas Funding Program Tenth tranche fully issued and paid-up Leuven, BELGIUM, 05 March – 07.00 PM CET – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company based in Leuven, today communicates it has r...
Information on the Total Number of Voting Rights (Denominator) following Conversion Notices from Atlas Atlas Special Opportunities, LLC has converted 6 convertible bonds in Oxurion resulting in a EUR 150,000 capital increase. This is part of Atlas Special Opportunities, LLC’s EUR...
Total Potential Development and Commercial Milestones of $3 2 M plus Royalties Leuven, BELGIUM, Boston, MA, US – July 25 , 2023 – 8 :00 a m CET – Oxurion NV (Euronext Brussels: OXUR) a biopharmaceutical compa...
Leuven, BELGIUM, Boston, MA, US – June 1 5 , 2023 – 7 pm CET – Oxurion NV (Euronext Brussels: OXUR) a biopharmaceutical company developing next-generation standard of care ophthalmic therapies, with clinical stage assets in vascular retinal disor...
Regulated Information - Denominator Atlas Special Opportunities, LLC has converted 6 convertible bonds in Oxurion resulting in a EUR 150 ,000 capital increase. This is part of Atlas Special Opportunities, LLC ’s EUR 20 million Capit...
News, Short Squeeze, Breakout and More Instantly...
Publication Annual Report – Annual Shareholders' Meeting Leuven, BELGIUM – April 15, 2024 – 05:00 PM CET Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, has today published its annual report for the financial year 2023. The...
Oxurion Receives EUR 450,000 in the framework of the Atlas Funding Program Eleventh tranche fully issued and paid-up Leuven, BELGIUM, 10 April 2024 – 07.00 PM CET – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company based in Leuven, today communicates ...
Postponement Annual Shareholders Meeting - Amendment financial calendar Leuven, BELGIUM – April 5, 2024 – 02:00 PM CET Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, today made the following announcement regarding its financial c...